• 1
    Bakris GL, Weber MA, Black HR, et al. Clinical efficacy and safety profiles of AT1 receptor antagonist. Cardiovasc Rev Rep. 1999;20:77100.
  • 2
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637645.
  • 3
    Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999;33:14061413.
  • 4
    Nishikawa K, Naka T, Chatani F, et al. Candesartan cilexetil; a review of its preclinical pharmacology. J Hum Hypertens. 1997;11(suppl 2):S9S17.
  • 5
    Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure. 1998;7:5359.
  • 6
    Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Heart Dis. 1999;1:5257.
  • 7
    Lacourciere Y, Asmar R, for the Candesartan/Losartan Study Investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Am J Hypertens. 1999;12:11811187.
  • 8
    National High Blood Pressure Education Program Working Group. Report on primary prevention of hypertension. Arch Intern Med. 1993;153:186208.
  • 9
    Stamler J, Stamler R, Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598615.
  • 10
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertensive Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 11
    Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N Engl J Med. 1993: 328: 914921.
  • 12
    Ohman KP, Milon H, Valnes K. Candesartan cilexetil-HCT in primary hypertension insufficiently controlled on monotherapy—a comparison with losartan-HCT. Am J Hypertens. 2000;13(4, pt 2):137A.